Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Sess
Go back to Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Sess| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 82.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $82.00 | 52 Week High | $8.22 | |||
| Open | $82.00 | 52 Week Low | $3.07 | |||
| Day High | $82.00 | P/E | N/A | |||
| Day Low | $82.00 | EPS | $-1.30 | |||
| Volume | 291 | |||||
